Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Italy, Germany, Spain, France, Poland, Czechia, Canada, South Korea, Australia, Sweden, Denmark, Austria, Portugal, Israel and Netherlands registers with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor. Synced 19 Nov 2026
42Current trials
30Recruiting now
18Drugs in these trials
15Trial registers
At a glance

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano is the lead sponsor of 42 current clinical trials in our Italy, Germany, Spain, France, Poland, Czechia, Canada, South Korea, Australia, Sweden, Denmark, Austria, Portugal, Israel and Netherlands registers. 30 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Abemaciclib, Temozolomide and 5Fluorouracil. The most-studied condition is Endometrial Cancer.

ClinicalTrials.gov trials by status

  • Recruiting3071%
  • Not yet open614%
  • Active, closed614%

Trials by phase

  • Observational2764%
  • Phase 2717%
  • Not applicable37%
  • Phase 1/225%
  • Phase 325%
  • Phase 412%
01

Clinical trials sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

42 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
NCT04689347 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer
Phase 1/2 Recruiting 2021-01 Italy
REtroperitoneal SArcoma Registry: an International Prospective Initiative
NCT03838718 · Retroperitoneal Sarcoma
Observational Recruiting 2016-09 Germany, France, Spain, Italy, Poland, Canada, South Korea, Australia
The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
NCT05483374 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Nasopharynx Cancer, Nasal Cavity and Paranasal Sinus Cancer
Observational Recruiting 2022-05 Germany, Italy, Czechia
Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment
NCT05649943 · ClinicalTrials.gov ↗ · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Not applicable Recruiting 2023-03 Italy
Immunological Phenotype of Desmoid-fibromatosis-affected Patients.
NCT07496242 · ClinicalTrials.gov ↗ · Desmoid-Type Fibromatosis
Observational Recruiting 2025-05 Italy, Netherlands
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
NCT06408441 · ClinicalTrials.gov ↗ · Epithelioid Hemangioendothelioma, Sarcoma,Soft Tissue
Observational Recruiting 2023-12 Germany, France, Spain, Italy, Sweden, Denmark, Poland, Austria, Portugal
Microbiota-guided Radiotherapy for Head and Neck Cancer
NCT07253402 · ClinicalTrials.gov ↗ · Head and Neck Cancer
Observational Recruiting 2025-10 Italy
DianaWeb: Before and After Study Online Based Participatory Research on Breast Cancer Women
NCT05057598 · ClinicalTrials.gov ↗ · Breast Cancer
Not applicable Recruiting 2016-06 Italy
A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma
NCT07507578 · ClinicalTrials.gov ↗ · Adenoid Cystic Carcinoma of the Salivary Gland, Adenoid Cystic Carcinoma of the Head and Neck
Observational Recruiting 2025-03 Italy
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
NCT05537922 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell
Observational Recruiting 2022-10 Spain, Israel
Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer
NCT06726291 · ClinicalTrials.gov ↗ · Endometrial Cancer
Drug: NEPA
Phase 4 Recruiting 2024-02 Italy
Duodenal Polyposis Classification in FAP
NCT07199127 · ClinicalTrials.gov ↗ · Duodenum Cancer, Familial Adenomatous Polyposis, Duodenal Polyposis
Observational Recruiting 2018-02 Italy
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)
NCT06594679 · ClinicalTrials.gov ↗ · Ovarian Cancer
Phase 1/2 Recruiting 2024-09 Italy
Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments
NCT06862934 · Intrahepatic Cholangiocarcinoma (Icc)
Observational Recruiting 2025-03 Italy
Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)
NCT06361784 · ClinicalTrials.gov ↗ · Locally Advanced Lung Non-Small Cell Carcinoma
Observational Recruiting 2024-03 Italy
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
NCT05621837 · ClinicalTrials.gov ↗ · Melanoma, Breast Cancer, Renal Cell Carcinoma
Observational Recruiting 2022-03 Italy
TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients
NCT05316922 · ClinicalTrials.gov ↗ · Hypothyroidism; Irradiation
Phase 3 Recruiting 2021-12 Italy
Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia
NCT06611020 · ClinicalTrials.gov ↗ · Cervical Intraepithelial Neoplasia
Observational Recruiting 2020-01 Italy
Matching Primary Tumor and Blood Gene Expression Analysis of HPV-negative Squamous Head and Neck Cancers
NCT07512921 · ClinicalTrials.gov ↗ · Head and Neck (HNSCC)
Observational Recruiting 2025-02 Italy
Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
NCT06986486 · ClinicalTrials.gov ↗ · Perihilar Cholangiocarcinoma, Klatskin Tumor
Observational Recruiting 2025-06 Italy
Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients
NCT06800391 · ClinicalTrials.gov ↗ · Pseudomyxoma Peritonei
Phase 2 Recruiting 2024-11 Italy
APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
NCT05550961 · ClinicalTrials.gov ↗ · NSCLC, Cancer, Lung Cancer
Observational Recruiting 2022-10 Italy
Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer
NCT06938724 · ClinicalTrials.gov ↗ · Breast Neoplasm Malignant Female
Phase 2 Recruiting 2025-07 Italy
The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.
NCT04403867 · ClinicalTrials.gov ↗ · Endometrial Cancer, Cervical Cancer, Sentinel Lymph Node
Observational Recruiting 2020-01 Italy
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
NCT06805812 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic
Observational Recruiting 2023-05 Italy
Epithelioid Haemangioendothelioma Observational Study
NCT06680401 · ClinicalTrials.gov ↗ · Clinical Presentation, Natural History, Treatment Outcomes
Observational Recruiting 2021-02 Italy
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
NCT05136326 · ClinicalTrials.gov ↗ · Rectal Cancer
Phase 2 Recruiting 2021-12 Italy
RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
NCT07030569 · ClinicalTrials.gov ↗ · Radiomic, Radiomics, Breast Cancer Metastatic
Observational Recruiting 2024-02 Italy
A Composite Assay for HER2-positive Early-stage Breast Cancer Management
NCT06762977 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3), HER2
Observational Recruiting 2024-11 Italy
Multimodality Treatments of HPV-related Lesions of the Female Genital Tract
NCT05938192 · ClinicalTrials.gov ↗ · HPV, Cervical Cancer, Cervix Lesion
Observational Recruiting 2020-07 Italy
Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
NCT06528483 · ClinicalTrials.gov ↗ · Bladder Cancer, Bladder Urothelial Carcinoma, Bladder Neoplasm
Phase 2 Not yet open 2024-12 Italy
Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr
NCT06799624 · ClinicalTrials.gov ↗ · Uterine Cancer
Observational Not yet open 2026-01 Italy
High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma
NCT06480396 · ClinicalTrials.gov ↗ · Sarcoma,Soft Tissue, Sarcoma Retroperitoneal
Phase 3 Not yet open 2024-11 Italy
Revisiting the Concept of Nerve Sparing Radical Hysterectomy
NCT06999824 · ClinicalTrials.gov ↗ · Cervical Cancers
Observational Not yet open 2025-06 Italy
Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)
NCT06086288 · ClinicalTrials.gov ↗ · Merkel Cell Carcinoma
Phase 2 Not yet open 2023-11 Italy
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
NCT05703997 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma
Phase 2 Not yet open 2023-01 Italy
Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)
NCT07461246 · ClinicalTrials.gov ↗ · Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP), MUTYH-Associated Polyposis (MAP)
Observational Active, closed 2024-05 Italy
Multiomics Approach in Metastatic Clear Renal Cell Carcnoma
NCT05782400 · ClinicalTrials.gov ↗ · Metastatic Clear Cell Renal Carcinoma
Observational Active, closed 2023-02 Italy
Non-invasive Detection of Breast Cancer by Breath Analysis
NCT06499077 · ClinicalTrials.gov ↗ · Breast Neoplasm Female
Observational Active, closed 2021-06 Italy
AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs
NCT06320184 · ClinicalTrials.gov ↗ · Lung Cancer, Blood Biomarkers
Observational Active, closed 2023-04 Italy
Radiomics and Molecular Classification in Endometrial Cancer
NCT06963385 · ClinicalTrials.gov ↗ · Endometrial Cancer, Uterine Cancer, Endometrium Tumor
Not applicable Active, closed 2021-01 Italy
Screening and Multiple Intervention on Lung Epidemics
NCT03654105 · ClinicalTrials.gov ↗ · Inflammation, Smoking Cessation, Diet Modification
Phase 2 Active, closed 2019-07 Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials

18 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials

79 conditions
Endometrial Cancer3Head and Neck Cancer2Sarcoma,Soft Tissue2Uterine Cancer2Breast Cancer2Lung Cancer2Cervical Cancer2Breast Cancer Stage IV2Nasopharynx Cancer1Nasal Cavity and Paranasal Sinus Cancer1Salivary Gland Cancer1Retroperitoneal Sarcoma1Epithelioid Hemangioendothelioma1Non Small Cell Lung Cancer1Lung Cancer Metastatic1Lung Cancer, Nonsmall Cell1Lung Adenocarcinoma1Metastatic Colorectal Cancer1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)1Bladder Cancer1Bladder Urothelial Carcinoma1Bladder Neoplasm1Muscle-Invasive Bladder Carcinoma1Familial Adenomatous Polyposis (FAP)1
06

Questions about Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials

How many clinical trials does Fondazione IRCCS Istituto Nazionale dei Tumori, Milano sponsor?

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano is the lead sponsor of 42 current trials on ClinicalTrials.gov in our Italy, Germany, Spain, France, Poland, Czechia, Canada, South Korea, Australia, Sweden, Denmark, Austria, Portugal, Israel and Netherlands registers, as of the registry sync on 19 November 2026. Completed and withdrawn studies are not counted.

Are Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials recruiting?

Yes. 30 of its 42 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Fondazione IRCCS Istituto Nazionale dei Tumori, Milano testing?

Its current trials name 18 drugs and biologicals as interventions. The most frequent are Abemaciclib (2), Temozolomide (2), 5Fluorouracil (1), Acetylsalicylic acid (1) and Atezolizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.